The collaboration will focus on developing a customized version of the SG EZ-be Pod®, a wearable drug delivery device, for Bexson’s proprietary ketamine formulation, BB106.
Lead Product(s): Ketamine Hydrochloride
Therapeutic Area: Neurology Product Name: BB106
Highest Development Status: Undisclosed Product Type: Small molecule
Partner/Sponsor/Collaborator: Bexson Biomedical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration September 21, 2020